Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 26;3(2):68-70.
doi: 10.14744/hf.2022.2022.0012. eCollection 2022 May.

Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis

Seyda Nur Dagli  1 , Cumali Efe  2
Affiliations
Review

Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis

Seyda Nur Dagli et al. Hepatol Forum. .

Abstract

Severe acute respiratory syndrome coronavirus 2 is a highly transmissible and pathogenic virus that leads to coronavirus disease 2019 (COVID-19). The preexisting liver diseases alter the course of COVID-19. Therefore, specific management strategies must be considered in individuals with chronic liver diseases (CLDs) and COVID-19. Autoimmune hepatitis (AIH) is a rare immune-mediated liver disease. Patients with AIH require life-long treatment with immunosuppressive drugs that may increase the risk of poor COVID-19 outcomes. The stage of underlying liver disease is another factor that can affect the clinical outcomes of COVID-19 in patients with AIH. In this review, we aim to provide relevant issues that will be helpful to clinicians in understanding and improving the clinical care for patients with AIH during the pandemic.

Keywords: Autoimmunity; azathioprine; immunosuppression; liver failure; liver transplantation; steroids.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest to declare.

References

    1. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora’s box-another novel coronavirus. N Engl J Med. 2020;382(14):1293–1295. - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776. - PubMed
    1. Yapalı S. What hepatologists need to know about COVID-19? Hepatology Forum. 2020;2(1):41–43. - PMC - PubMed
    1. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021;19(7):1469–1479. e19. - PMC - PubMed
    1. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases. Hepatology. 2020;72(2):671–722. - PubMed

LinkOut - more resources